Effects on Vitamin D,Bone and the Kidney of Switching from Fixed-Dose Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz to Darunavir/ Ritonavir Monotherapy: A Randomized,Controlled Trial (MIDAS)

May M.T. , Gompels M. , Delpech V. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study. AIDS 2014; 28: 1193–1202.

Guaraldi G. , Orlando G. , Zona S. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120–1126.

Arribas J.R. , Clumeck N. , Nelson M. , Hill A. , van Delft Y. , Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/ml at baseline. HIV Med 2012; 13: 398–405.

Katlama C. , Valantin M.A. , Algarte-Genin M. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365–2374.

Paton N.I. , Stöhr W. , Arenas-Pinto A. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV 2015; 2: e417–e426.

Orkin C. , Wohl D.A. , Williams A. , Deckx H. Vitamin D deficiency in HIV: a shadow on long-term management? AIDS Rev 2014; 16: 59–74.

Hyppönen E. , Berry D. , Cortina-Borja M. , Power C. 25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis in the 1958 British Birth Cohort. PLoS ONE 2010; 5: e10801.

Amer M. , Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol 2012; 109: 226–230.

Mellenthin L. , Wallaschofski H. , Grotevendt A. , Volzke H. , Nauck M. , Hannemann A. Association between serum vitamin D concentrations and inflammatory markers in the general adult population. Metabolism 2014; 63: 1056–1062.

De Vita F. , Lauretani F. , Bauer J. Relationship between vitamin D and inflammatory markers in older individuals. Age (Dordr) 2014; 36: 9694.

Wang L. , Song Y. , Manson J.E. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012; 5: 819–829.

Garland C.F. , Kim J.J. , Mohr S.B. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am J Public Health 2014; 104: e43–e50.

Welz T. , Childs K. , Ibrahim F. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24: 1923–1928.

Wohl D.A. , Orkin C. , Doroana M. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther 2014; 19: 191–200.

Schwartz J.B. , Moore K.L. , Yin M. Relationship of vitamin D, HIV, HIV treatment, and lipid levels in the Women's Interagency HIV Study of HIV-infected and uninfected women in the United States. J Int Assoc Provid AIDS Care 2014; 13: 250–259.

Shepherd L. , Souberbielle J.C. , Bastard J.P. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis 2014; 210: 234–243.

Legeai C. , Vigouroux C. , Souberbielle J.C. Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 <<COPANA>> cohort study. PLoS ONE 2013; 8: e74868.

Eckard A.R. , Judd S.E. , Ziegler T.R. Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antivir Ther 2012; 17: 1069–1078.

Ansemant T. , Mahy S. , Piroth C. Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients. BMC Infect Dis 2013; 13: 7.

Overton E.T. , Chan E.S. , Brown T.T. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med 2015; 162: 815–824.

Fabre-Mersseman V. , Tubiana R. , Papagno L. Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. AIDS 2014; 28: 2677–2682.

Chen N. , Wan Z. , Han S.F. , Li B.Y. , Zhang Z.L. , Qin L.Q. Effect of vitamin D supplementation on the level of circulating high-sensitivity C-reactive protein: a meta-analysis of randomized controlled trials. Nutrients 2014; 6: 2206–2216.

Shah S. , Wilson D.M. , Bachrach L.K. Large doses of vitamin D fail to increase 25-hydroxyvitamin D levels or to alter cardiovascular risk factors in obese adolescents: a pilot study. J Adolesc Health 2015; 57: 19–23.

Stellbrink H.J. , Orkin C. , Arribas J.R. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51: 963–972.

Rasmussen T.A. , Jensen D. , Tolstrup M. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS ONE 2012; 7: e32445.

Huang J.S. , Hughes M.D. , Riddler S.A. , Haubrich R.H. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 2013; 14: 224–234.

Childs K.E. , Fishman S.L. , Constable C. Short communication: inadequate vitamin d exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 2010; 26: 855–859.

Hamzah L. , Booth J.W. , Jose S. Renal tubular disease in the era of combination antiretroviral therapy. AIDS 2015; 29: 1831–1836.

Mocroft A. , Lundgren J.D. , Ross M. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV 2016; 3: e23–e32.

Hall A.M. , Edwards S.G. , Lapsley M. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis 2009; 54: 1034–1042.

Campbell L.J. , Dew T. , Salota R. Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol 2012; 13: 85.

Fox J. , Peters B. , Prakash M. , Arribas J. , Hill A. , Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses 2011; 27: 29–34.

Bloch M. , Tong W. , Hoy J. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med 2014; 15: 373–380.

Jose S. , Hamzah L. , Campbell L.J. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis 2014; 210: 363–373.

Negredo E. , Domingo P. , Perez-Alvarez N. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother 2014; 69: 3368–3371.

Burling K.A. , Cutillas P.R. , Church D. , Lapsley M. , Norden A.G. Analysis of molecular forms of urine retinol-binding protein in Fanconi syndrome and design of an accurate immunoassay. Clin Chim Acta 2012; 413: 483–489.

Ibrahim F. , Hamzah L. , Jones R. , Nitsch D. , Sabin C. , Post F.A. Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Nephrol Dial Transplant 2012; 27: 2291–2297.

Stevens L.A. , Coresh J. , Schmid C.H. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395–406.

Kenny A.P. , Glen A.C. Tests of phosphate reabsorption. Lancet 1973; 2: 158.

Ellfolk M. , Norlin M. , Gyllensten K. , Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009; 75: 1392–1399.

Pascussi J.M. , Robert A. , Nguyen M. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115: 177–186.

Cozzolino M. , Vidal M. , Arcidiacono M.V. , Tebas P. , Yarasheski K.E. , Dusso A.S. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17: 513–520.

Gallant J.E. , Staszewski S. , Pozniak A.L. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191–201.

McComsey G.A. , Kitch D. , Daar E.S. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791–1801.

Guaraldi G. , Zona S. , Cossarizza A. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial. Int J STD AIDS 2014; 25: 207–212.

Rozenberg S. , Lanoy E. , Bentata M. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). AIDS Res Hum Retroviruses 2012; 28: 972–980.

Huang J. , Meixner L. , Fernandez S. , McCutchan J.A. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009; 23: 51–57.

McComsey G.A. , Kendall M.A. , Tebas P. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21: 2473–2482.

Bolland M.J. , Grey A.B. , Horne A.M. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007; 92: 1283–1288.

Eastell R. , Vrijens B. , Cahall D.L. , Ringe J.D. , Garnero P. , Watts N.B. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 2011; 26: 1662–1669.

Grigsby I.F. , Pham L. , Mansky L.M. , Gopalakrishnan R. , Mansky K.C. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 6: 41–47.

Grigsby I.F. , Pham L. , Gopalakrishnan R. , Mansky L.M. , Mansky K.C. Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochem Biophys Res Commun 2010; 391: 1324–1329.

Grigsby I.F. , Pham L. , Mansky L.M. , Gopalakrishnan R. , Carlson A.E. , Mansky K.C. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010; 394: 48–53.

Lepist E.I. , Zhang X. , Hao J. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 2014; 86: 350–357.

de Lastours V. , Ferrari Rafael De Silva E. , Daudon M. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 2013; 68: 1850–1856.